30,264 Results

Celgene acquires Juno Therapeutics and with JCAR 017

 Added 21 hours ago

Celgene Corporation and Juno Therapeutics, Inc. have announced the signing of a definitive merger agreement.

Chronic lymphocytic leukaemia treatment to be removed

 Added 21 hours ago

Genmab announces it is removing Arzerra from the chronic lymphocytic leukaemia market outside the US.

Five-year study of NX 1207 shows cut in surgery or radiotherapy for prostate cancer patients.

 Added 21 hours ago

Nymox Pharmaceutical reported top-line 5-year results from Nymox's U.S. Study NX03-0040 of NX 1207 (fexapotide triflutate) in prostate cancer. 

EC approves Adcetris for CD30-positive cutaneous T-cell lymphoma.

 Added 21 hours ago

The European Commission (EC) extended the current conditional marketing authorization of Adcetris (brentuximab vedotin).

Phase III study of Cinqair did not meet endpoint in Severe Eosinophilic Asthma.

 Added 21 hours ago

No reduction in the frequency of clinical asthma exacerbations (CAEs).

Investigational DNA vaccine in unsuccessful trial

 Added 21 hours ago

Phase III HELIOS trial of ASP 0113 fails to meet endpoints in cytomegalovirus.

FDA grants extended approval for Trisenox to treat acute promyelocytic leukemia

 Added 21 hours ago

The approval was based on a Priority Review by the FDA on data from published scientific literature and a review of Teva’s global safety database for arsenic trioxide.

Glucose Control and Weight Change Associated with Treatment with Exenatide Compared with Basal Insulin: A Retrospective Study.

Introduction: The aim of the study was to compare glycemic and weight change outcomes for type 2 diabetes patients treated with either exenatide once-weekly (EQW) or exenatide twice-daily (EBID)...

Real-world clinical outcomes and predictors of glycaemic and weight response to exenatide once weekly in patients with type 2 diabetes: The CIBELES project.

Aims: To evaluate in a real-world setting the effectiveness of exenatide once-weekly (ExQW) in patients with T2D and to determine predictors of glycaemic and weight response to this drug at 6 months.

Exenatide Increases IL-1RA Concentration and Induces Nrf-2-Keap-1 Regulated Anti-oxidant Enzymes: Relevance to β Cell Function.

Purpose: We have previously demonstrated anti-inflammatory and antioxidant effects of exenatide. We have now hypothesized that exenatide also increases the plasma concentration of IL-1RA...

Load more